Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies

Current combination therapies elicit high response rates in B cell malignancies, often using CD20 antibodies as the backbone of therapy. However, many patients eventually relapse or develop progressive disease. Therefore, novel CD20 antibodies combining multiple effector mechanisms were generated. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Evers, Mitchell, Ten Broeke, Toine, Jansen, J.H. Marco, Nederend, Maaike, Hamdan, Firas, Reiding, Karli R., Meyer, Saskia, Moerer, Petra, Brinkman, Iris, Rösner, Thies, Lebbink, Robert Jan, Valerius, Thomas, Leusen, Jeanette H.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531568/
https://www.ncbi.nlm.nih.gov/pubmed/32744145
http://dx.doi.org/10.1080/19420862.2020.1795505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531568/
https://www.ncbi.nlm.nih.gov/pubmed/32744145
http://dx.doi.org/10.1080/19420862.2020.1795505

Ejemplares similares